UBS Group Increases Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,099.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by UBS Group from $1,090.00 to $1,099.00 in a research note published on Wednesday morning, Benzinga reports. UBS Group currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages also recently issued reports on REGN. Royal Bank of Canada reissued an outperform rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a report on Wednesday, March 13th. StockNews.com raised Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday, April 12th. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an outperform rating in a research note on Monday, February 5th. Finally, Barclays boosted their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an overweight rating in a report on Tuesday, January 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average price target of $976.41.

Regeneron Pharmaceuticals Stock Up 0.8 %

Regeneron Pharmaceuticals stock opened at $901.19 on Wednesday. The company has a market capitalization of $98.91 billion, a P/E ratio of 25.93, a PEG ratio of 2.58 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The stock has a 50-day simple moving average of $955.19 and a 200-day simple moving average of $890.52.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $10.96 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals will post 38.58 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,325,338. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,729 shares of company stock valued at $13,124,641. Insiders own 8.83% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of REGN. Eudaimonia Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.2% during the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 11 shares during the last quarter. Ronald Blue Trust Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after purchasing an additional 12 shares during the last quarter. Drive Wealth Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 12 shares during the last quarter. MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the period. Finally, LCM Capital Management Inc grew its position in shares of Regeneron Pharmaceuticals by 2.5% in the fourth quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock valued at $427,000 after purchasing an additional 12 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.